Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 58

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 58
---
utive effect:Potentially dilutive securitiesThree Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Stock options1,121,802 961,431 1,121,802 961,431 Warrants1,268,572 1,203,583 1,268,572 1,201,620 Total2,390,374 2,165,014 2,390,374 2,163,051 

12.    SEGMENT INFORMATION

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing and commercializing pharmaceutical products that target unmet needs in women's health. The CODM, who is the chief executive officer (“CEO”), manages and allocates resources to the operations of the Company on a consolidated basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented. In addition, substantially all of the Company's revenue was generated in the United States and substantially all of the Company's long-lived assets reside in the United States. The following table summarizes the segment's financial information including the Company’s significant segment expenses:

26

Three Months EndedJune 30,Six Months Ended June 30,2025202420252024Revenue:Royalty revenue$(21,172)$22,438 $4,255 $31,740 Total revenue(21,172)22,438 4,255 31,740 Segment operating expenses:Research and development:Direct program costs:Ovaprene1,316,372 2,979,486 2,812,101 5,163,358 Sildenafil Cream